

21 April 2026

Section 708A Cleansing Statement

This notice is given by Neurizon Therapeutics Limited ACN 094 006 023 (**ASX: NUZ**) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

- (a) it has today issued a total of 33,212,500 fully paid ordinary shares (**Shares**) at an issue price of \$0.08 (8 cents) per Share, in relation to the placement of Entitlement Offer Shortfall as announced by the Company on 16 April 2026;
- (b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph (5)(e) of section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) sections 674 and 674A of the Corporations Act; and
- (e) as at the date of this notice, there is no “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act.

The Appendix 2A relating to the issue of Shares was lodged earlier today.

-Ends-

This announcement is authorized for release by the Board of Directors of Neurizon Therapeutics Limited.

For further information, please contact:

Neurizon Therapeutics

Lidija Damjanovic

Marketing & Corporate Affairs

Email: lidija@neurizon.com

Phone: +61 (0) 425 700 504

Australia Investor Relations

Henry Jordan

Six Degrees Investor Relations

Email: henry.jordan@sdir.com.au

Phone: +61 (0) 431 271 538

U.S. Investor Relations

Matthew Selinger

Integrous Communications

Email: mselinger@integcom.us

Phone: +1 415-572-8152

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited.